Clinical markers of early disease in persons near onset of Huntington's disease

Neurology

Volumn 57, Issue 4, 2001, Pages 658-662

  Paulsen, Jane S ^a   Zhao, H ^b   Stout, J C ^c   Brinkman, R R ^d   Guttman, M ^e   Ross, C A ^f   Como, P ^b   Manning, C ^g   Hayden, M R ^d   Shoulson, I ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0035964234     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.4.658     Document Type: Article

References (42)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
2. When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases
3. Huntington's disease: Translating a CAG repeat into a pathogenic mechanism
4. Huntington disease: Another chapter rewritten
5. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative disease?
6. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA)
7. Genetic classification of primary neurodegenerative disease
8. Genetic neurodegenerative diseases: The human illness and transgenic models
9. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease
10. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease
11. Positron emission tomography in the early diagnosis of Huntington's disease
12. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease
13. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
14. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
15. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
16. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
17. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
18. The likelihood of being affected with Huntington's disease by a particular age, for a specific CAG size
19. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation
20. Evidence of presymptomatic cognitive decline in Huntington's disease
21. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers
22. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers
23. Presymptomatic neuropsychological impairment in Huntington's disease
24. Premorbid psychometric indicators of the gene for Huntington's disease
25. Motor changes in presymptomatic Huntington disease gene carriers
26. Unified Huntington's disease rating scale: Reliability and consistency
27. A study of inter-rater reliability of motor diagnosis of Huntington's disease
28. Studies of interference in serial verbal reactions
29. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype
30. Random-effects models for longitudinal data
31. Are there neuropsychologic manifestations of the gene for Huntington's disease in asymptomatic, at-risk individuals?
32. Initiation and execution of movement sequences in those suffering from and at-risk of developing Huntington's disease
33. A brief assessment of frontal and sub-cortical functions in dementia
34. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease
35. Neuropsychological characteristics of Huntington's disease carriers: A double blind study
36. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease
37. Evidence for specific cognitive deficits in preclinical Huntington's disease
38. Odor identification in Huntington's disease patients and asymptomatic gene carriers
39. Cognitive manifestations of Huntington's disease in relation to genetic structure and clinical onset
40. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease